Zafirlukast in asthma; evidence for tolerance and rebound on cessation

D. W. Reid, N. Misso, P. J. Thompson, H. E. Walters (Hobart, Perth, Australia)

Source: Annual Congress 2003 - Asthma and rhinitis
Session: Asthma and rhinitis
Session type: Thematic Poster Session
Number: 763
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. W. Reid, N. Misso, P. J. Thompson, H. E. Walters (Hobart, Perth, Australia). Zafirlukast in asthma; evidence for tolerance and rebound on cessation. Eur Respir J 2003; 22: Suppl. 45, 763

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
COPD and asthma: the effect of glucocorticosteroid therapy on tolerance to physical activity
Source: Eur Respir J 2005; 26: Suppl. 49, 295s
Year: 2005

Bronchodilator tolerance: the impact of increasing bronchoconstriction
Source: Eur Respir J 2003; 21: 810-815
Year: 2003



R411 treatment reduces asthma exacerbations and attenuates FEV1 fall following steroid withdrawal in moderate asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 252s
Year: 2005

The effect of bupropion on smoking cessation and sleep physiology in COPD and asthma patients
Source: International Congress 2018 – Tobacco use and cessation interventions in patients with respiratory, cardiovascular and mental health problems and other populations
Year: 2018

Mechanisms of improved exercise tolerance in COPD in response to tiotropium
Source: Eur Respir J 2002; 20: Suppl. 38, 288s
Year: 2002

Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol
Source: Eur Respir J 2001; 17: 368-373
Year: 2001



Varenicline is a cost-effective pharmacotherapy in smoking cessation of nicotine dependent patients with mild to moderate COPD
Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Year: 2012

Predictors of asthma exacerbation after treatment cessation
Source: Eur Respir J 2003; 22: Suppl. 45, 35s
Year: 2003

Increased respiratory symptoms in COPD patients on withdrawal of therapy: evidence of long-term efficacy gains with formoterol turbuhaler
Source: Eur Respir J 2002; 20: Suppl. 38, 243s
Year: 2002

The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015


Is omalizumab response influenced by passive smoking in severe asthma?
Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Year: 2018


Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Source: Eur Respir J 2001; 17: 374-379
Year: 2001



Three month treatment with formoterol in mild asthma: efficacy and side effects
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

Smoking cessation and prevention
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=242
Year: 2006

Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children
Source: Eur Respir J 2006; 28: 291-295
Year: 2006



Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


Smoking cessation and COPD
Source: Eur Respir Rev 2013; 22: 37-43
Year: 2013



Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study
Source: International Congress 2018 – Eosinophils in airway disease
Year: 2018




Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013


Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020